DEPICT-1 results

The 24-week results from a trial, DEPICT-1, people with Type 1 diabetes taking the oral selective SGLT-2 inhibitor class of diabetes medicines show that dapagliflozin, as an adjunct to insulin, provides significant and clinically relevant benefits in terms of glycaemic control and weight reduction, together with a reduction in insulin dose, and is not associated with an increase in the occurrence of hypoglycaemia or diabetic ketoacidosis.

Read more about SGLT-2 inhibitors HERE.

News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal. We cover diabetes news, diabetes management equipment (diabetes kit) and news about food suitable for a diabetic diet. Go to the top of this page to sign up – we just need your email address. www.desang-magazine.co.uk


Open publication

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags